// App-Quantinova.ai

2532 : First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.

Researchers

Presenter

  • Herbert Hurwitz

Principal Investigators

  • Henry Clement Pitot

  • Elisabeth Rouits

  • Claudio Zanna

  • J. Mel Sorensen

  • David C. Smith

  • Jeffrey Mark Brill

  • Gregoire Vuagniaux

Medical Centers

  • Debiopharm International SA, Lausanne, Switzerland

  • Duke University Medical Center, Durham, NC

  • Galera Therapeutics, Inc, Malvern, PA

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Mayo Clinic, Rochester, MN

  • Galera Therapeutics, Inc, Malvern, PA

Locations

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • AT-406

Outcome

  • Indeterminate

Study Design

  • adaptive

  • pharmacodynamics

Phase

  • I

Study Id's

  • NCT01078649

Sponsors

  • Ascenta Therapeutics, Inc.

  • Debiopharm

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved